Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | ITK | Q08881 | 4/20 | 0.56 |
| ▸ | SYK | P43405 | 8/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 4/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655444 | 0.85 | EGFR (0.51) | EGFRITKSYKBCL6AURKA | |
| SCHEMBL654088 | 0.84 | SYK (0.74) | SYKBCL6AURKANCOR2 | |
| SCHEMBL27612425 | 0.81 | EGFR (0.53) | EGFRITKSYKAURKA | |
| SCHEMBL2103835 | 0.80 | BCL6 (0.60) | EGFRITKSYKP2RX3BCL6 | |
| SCHEMBL653572 | 0.78 | AURKA (0.51) | ITKSYKBCL6AURKAALDH1A1 | |
| SCHEMBL27612424 | 0.78 | EGFR (0.41) | EGFRITKSYKP2RX3BCL6 | |
| SCHEMBL15741405 | 0.75 | AURKA (0.61) | ITKSYKBCL6AURKAALDH1A1 | |
| SCHEMBL31691271 | 0.75 | EGFR (0.42) | EGFRITKSYKP2RX3ALDH1A1 | |
| SCHEMBL30838848 | 0.75 | TRPV3 (0.42) | EGFRITKSYKALDH1A1 | |
| SCHEMBL29235943 | 0.75 | TRPV3 (0.42) | EGFRITKSYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |